Precigen

Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases

Retrieved on: 
木曜日, 5月 16, 2024
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, COVID-19, Patent, FDA, Sale, Regeneron Pharmaceuticals, Traction, Stem cell, Pulmonary fibrosis, COPD, Precigen, Inflammation, TSOI, History, Pharmaceutical industry

Additionally, the Company has filed a Phase I/II clinical trial for COPD and possesses preclinical data for pulmonary fibrosis.

Key Points: 
  • Additionally, the Company has filed a Phase I/II clinical trial for COPD and possesses preclinical data for pulmonary fibrosis.
  • “We anticipate significant value in the current patent based on other companies working in the area of T regulatory cells.
  • “At Therapeutic Solutions International we are building a critical mass of clinical data, scientific discoveries, and patents4,” said Timothy Dixon, President, and CEO of the Company and co-inventor.
  • “We believe we are developing significant traction which will result in partnerships and co-development deals.”

Immunology Based Suicide Prevention Company Campbell Neurosciences Announces Appointment of Public Company Veteran Raymond Oliver as Chairman of the Board

Retrieved on: 
木曜日, 5月 9, 2024
Pharmaceutical, Health, Neurology, Mental Health, Stanford University, Sale, Acceleration, Precigen, Holding company, TSOI, Depression, DSM-IV codes, History, Entrepreneurship, Science, CUSIP, Drug development

Therapeutic Solutions International pre-spin-off company, Campbell Neurosciences, Inc., announced today appointment of seasoned public company veteran Mr. Raymond Oliver as Chairman of its Board of Directors.

Key Points: 
  • Therapeutic Solutions International pre-spin-off company, Campbell Neurosciences, Inc., announced today appointment of seasoned public company veteran Mr. Raymond Oliver as Chairman of its Board of Directors.
  • This move is part of a larger strategy the suicide prevention company is implementing towards reaching its goal of a public listing.
  • This elective grant to TSOI shareholders is anticipated to increase the number of Campbell Neurosciences shareholders, thus accelerating the pathway towards public listing.
  • “I am humbled and honored to continue the work of Mr. Timothy Dixon as Chairman of Campbell Neurosciences.

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Retrieved on: 
水曜日, 5月 8, 2024
Precigen, Infection, Annual report, Security (finance), ASCO, Risk, Patient, Society, RRP, Annual general meeting

Additional details for the June 3rd conference call will be announced at a later date.

Key Points: 
  • Additional details for the June 3rd conference call will be announced at a later date.
  • For information on Precigen's upcoming events, please visit the Company website Events & Presentations section at investors.precigen.com/events-presentations .
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .

Actym Therapeutics Appoints Thomas Smart as CEO

Retrieved on: 
水曜日, 4月 24, 2024
Sale, University, Precigen, David G. Booth, Master of Business Administration, Safety, Chairperson, Business administration, RNA, Tumor microenvironment, Business, Strategic planning, Cornell University, Genetics Institute, DNA, Therapy, SVP, Acquisition, SITC, Peptide, AACR, Antibody, CBO, Organization, TME

BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.

Key Points: 
  • BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
  • The STACT approach provides both efficacy and safety advantages by leveraging a genetically modified bacteria vehicle, systemically administered, that achieves tissue-specific delivery of large nucleic acid payloads," said Thomas Smart, CEO of Actym.
  • Mr. Smart has a distinguished 25-year career as a biotech executive, demonstrating dynamic leadership in roles such as CEO, CBO, SVP, and Board Member.
  • Before joining Actym Therapeutics, Mr. Smart founded Gravitas Therapeutics, where he served as CEO and Board Chair and orchestrated the acquisition and subsequent sale of the clinical-stage antifungal asset, GR-2397, to Basilea Pharmaceutica Ltd (SIX: BSLN) in October 2023.

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Retrieved on: 
火曜日, 3月 12, 2024
Cantor Fitzgerald, Immunotherapy, Patient, Doctor of Philosophy, NIH, Infection, Precigen, RRP, Bangladesh Technical Education Board

The event will be hosted by Jennifer Kim, Biotechnology Analyst at Cantor Fitzgerald, and participants will include Helen Sabzevari, PhD, President and CEO of Precigen, and Clint T. Allen, MD, Principal Investigator, Section on Translational Tumor Immunology at the National Institutes of Health (NIH), and a lead investigator for the PRGN-2012 clinical study.

Key Points: 
  • The event will be hosted by Jennifer Kim, Biotechnology Analyst at Cantor Fitzgerald, and participants will include Helen Sabzevari, PhD, President and CEO of Precigen, and Clint T. Allen, MD, Principal Investigator, Section on Translational Tumor Immunology at the National Institutes of Health (NIH), and a lead investigator for the PRGN-2012 clinical study.
  • Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Retrieved on: 
火曜日, 3月 5, 2024
International, Risk, Annual report, Conference, Precigen, Patient, Security (finance), Infection

The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.

Key Points: 
  • The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.
  • The conference call may be accessed by dialing 1-888-664-6383 (North America) or 1-416-764-8650 (International) to join the Precigen Conference Call.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
火曜日, 2月 6, 2024
Precigen, Security (finance), Patient, Annual report, Infection, Doctor of Philosophy, Risk, Conference

GERMANTOWN, Md., Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024.

Key Points: 
  • GERMANTOWN, Md., Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024.
  • Precigen's company presentation will take place on Tuesday, February 13 from 3:20 PM to 3:50 PM EST.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Retrieved on: 
火曜日, 2月 6, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, McKinsey & Company, Shalini, Bristol Myers Squibb, Lactococcus lactis, Harvard University, Organon, Agenus, Patient, GPCR, Drug discovery, MBA, Endocrinology, Neurocrine Biosciences, Therapy, Assistant, Drug development, Hypoparathyroidism, Acquisition, Goldman Sachs, G protein-coupled receptor, Metabolism, University, Mirati Therapeutics, PTH1R, Precigen, Pharmacy, Internal medicine, Pharmaceutical industry

Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.

Key Points: 
  • Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.
  • Shalini brings a wealth of strategic, financial, and operational experience, having led or advised several successful private and public biotech companies.
  • Bernard Coulie brings more than two decades of senior leadership experience and drug development expertise to the Septerna board.
  • Shalini Sharp has been in the life sciences industry for over 25 years, having spent 14 years as a Chief Financial Officer.

Sage Therapeutics Announces Changes to Board of Directors

Retrieved on: 
月曜日, 1月 8, 2024
Research, Pharmaceutical, Consumer, Mental Health, Parenting, Clinical Trials, Science, Baby, Maternity, Women, Biotechnology, Neurology, Health, Johnson & Johnson, Chairperson, Retirement, Precigen, Therapy, Investment, Patient, Third Rock Ventures, Life

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company’s board of directors.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company’s board of directors.
  • Geno Germano has assumed the role of Chair of the Board of Directors.
  • Mr. Starr led the early efforts to launch Sage Therapeutics, served as CEO prior to the company’s initial public offering, and served as Chair of the Board since Sage went public in 2014.
  • “At the same time, I am thrilled to have Geno assume the role of Chair of the Board at a time of great momentum for Sage.

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
月曜日, 12月 18, 2023
Conference, Precigen, Doctor of Philosophy, Risk, Patient, Infection, Security (finance), Annual report

Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.

Key Points: 
  • Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .
  • The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.